ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Takeda sells 5 prescription drugs to China's Hasten for $322m

Blood pressure treatment Ebrantil part of Japanese company's latest asset sale

Japan's Takeda will sell off prescription drugs available in China, including the Ebrantil blood pressure reducer. (Photo by Nobuyoshi Shioda)

TOKYO -- Takeda Pharmaceutical will sell five prescription products to China's Hasten Biopharmaceutic in a $322 million deal as Japan's top drugmaker continues to slash debt from its acquisition of Ireland-based peer Shire.

The transaction is slated to close by the end of June and covers cardiovascular and metabolism treatments sold in mainland China, including the Ebrantil blood pressure reducer.

Net sales of these products reached $109.5 million in fiscal 2019. Sales personnel will be transferred to Hasten, while Takeda will produce and supply the products to the new owner.

Ebrantil is a product of Nycomed, a Swiss drug company Takeda acquired in 2011.

Takeda has been restructuring its business portfolio since the 2019 purchase of Shire, narrowing its specializations to five areas, such as oncology and rare diseases, and unloading noncore operations.

The value of its asset sales, including those yet to be closed, reaches up to $11.3 billion -- exceeding the company's divesture target of $10 billion.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more